Origin and Lineage of Differentiation of Kaposi's Sarcoma

卡波西肉瘤的起源和分化谱系

基本信息

  • 批准号:
    8839925
  • 负责人:
  • 金额:
    $ 17.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-13 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Kaposi sarcoma (KS) is the leading cancer in HIV+ persons in the US and world-wide. In some countries in Sub-Saharan Africa it is the most common cancer in the country. Unlike in the US both HIV+ men and women present with KS in South Africa. Crucial aspects of the biology and pathology of the KS tumor cell remain unknown. This represents a gap in our knowledge that prevents tumor-targeted therapies. Knowing the exact lineage and origin of the KS tumor cell is essential if we were to develop novel KS-specific therapies. These interventions, be it drugs or cytotoxic antibodies, must selectively target KS tumor cells and not the normal cells lining blood vessels in essential organs such as heart or kidney. Recent work from many groups found evidence for multiple cell types in KS and for multiple cell types that support KSHV replication: lymphatic endothelial cells (LEC), transdifferentiated vein endothelial cells (VEC), perictyes, mesenchymal cells akin to epithelial-mesenchymal transition (EMT) and stromal fibroblasts. In sum, 20 years after the discovery of KSHV, we still do not know exactly which cells make up a KS lesions, what the spectrum of KS lesions is, and if they respond differently to therapy. This R21 application seeks to address some of these questions through the Construction and analysis of a South African KS tissue microarray.
 描述(由申请人提供):卡波西肉瘤(KS)是美国和世界范围内 HIV + 人群的主要癌症。在撒哈拉以南非洲的一些国家,这是该国最常见的癌症。与美国不同的是,南非的艾滋病毒阳性男性和女性都患有 KS。 KS 肿瘤细胞的生物学和病理学的关键方面仍然未知。这代表了我们在阻碍肿瘤靶向治疗方面的知识空白。如果我们要开发新的 KS 特异性疗法,了解 KS 肿瘤细胞的确切谱系和起源至关重要。这些干预措施,无论是药物还是细胞毒性抗体,都必须选择性地针对 KS 肿瘤细胞,而不是心脏或肾脏等重要器官血管内壁的正常细胞。许多小组最近的工作发现了 KS 中多种细胞类型以及支持 KSHV 复制的多种细胞类型的证据:淋巴内皮细胞 (LEC)、转分化静脉内皮细胞 (VEC)、周细胞、类似于上皮间质转化 (EMT) 的间充质细胞和基质成纤维细胞。总之,在发现 KSHV 20 年后,我们仍然不知道到底哪些细胞构成了 KS 病变,KS 病变的范围是什么,以及它们对治疗的反应是否不同。该 R21 应用旨在通过构建和分析南非 KS 组织微阵列来解决其中一些问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dirk P Dittmer其他文献

Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
  • DOI:
    10.1186/1750-9378-7-s1-o9
  • 发表时间:
    2012-04-19
  • 期刊:
  • 影响因子:
    2.800
  • 作者:
    Dirk P Dittmer;Blossom Damania;Sang-Hoon Sin;Debasmita Roy
  • 通讯作者:
    Debasmita Roy
The use of high-dose azidothymidine in combination with chemotherapy upfront is an effective treatment approach for gamma-herpes virus-related non-Hodgkin’s lymphomas
  • DOI:
    10.1186/1750-9378-5-s1-a81
  • 发表时间:
    2010-10-11
  • 期刊:
  • 影响因子:
    2.800
  • 作者:
    Ulas Darda Bayraktar;Eileen Bernal;Lisa Cabral;William J Harrington;Dirk P Dittmer;Juan Carlos Ramos
  • 通讯作者:
    Juan Carlos Ramos

Dirk P Dittmer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dirk P Dittmer', 18)}}的其他基金

PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
  • 批准号:
    10334549
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
  • 批准号:
    10434864
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
  • 批准号:
    10652401
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
  • 批准号:
    10084558
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
  • 批准号:
    10579826
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
  • 批准号:
    10115683
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
  • 批准号:
    10238161
  • 财政年份:
    2020
  • 资助金额:
    $ 17.29万
  • 项目类别:
Planning for a National Non-Communicable Disease Center of Research Excellence
规划国家非传染性疾病卓越研究中心
  • 批准号:
    9337384
  • 财政年份:
    2016
  • 资助金额:
    $ 17.29万
  • 项目类别:
Planning for a National Non-Communicable Disease Center of Research Excellence
规划国家非传染性疾病卓越研究中心
  • 批准号:
    9193832
  • 财政年份:
    2016
  • 资助金额:
    $ 17.29万
  • 项目类别:
HIV and substances of abuse influence exosomes and endothelial cell function
HIV 和滥用物质影响外泌体和内皮细胞功能
  • 批准号:
    9304176
  • 财政年份:
    2015
  • 资助金额:
    $ 17.29万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.29万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了